Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more
Cynata Therapeutics Limited (CYYNF) - Total Assets
Latest total assets as of June 2025: $7.20 Million USD
Based on the latest financial reports, Cynata Therapeutics Limited (CYYNF) holds total assets worth $7.20 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cynata Therapeutics Limited - Total Assets Trend (2007–2025)
This chart illustrates how Cynata Therapeutics Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cynata Therapeutics Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Cynata Therapeutics Limited's total assets of $7.20 Million consist of 74.3% current assets and 25.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.2% |
| Accounts Receivable | $104.65K | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.85 Million | 25.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Cynata Therapeutics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cynata Therapeutics Limited's current assets represent 74.3% of total assets in 2025, a decrease from 98.1% in 2007.
- Cash Position: Cash and equivalents constituted 70.2% of total assets in 2025, down from 91.3% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 1.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 25.7% of total assets.
Cynata Therapeutics Limited Competitors by Total Assets
Key competitors of Cynata Therapeutics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Cynata Therapeutics Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cynata Therapeutics Limited generates 0.26x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cynata Therapeutics Limited is currently not profitable relative to its asset base.
Cynata Therapeutics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.40 | 5.58 | 20.08 |
| Quick Ratio | 4.40 | 5.58 | 20.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.13 Million | $ 5.37 Million | $ 13.16 Million |
Cynata Therapeutics Limited - Advanced Valuation Insights
This section examines the relationship between Cynata Therapeutics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.26 |
| Latest Market Cap to Assets Ratio | 3.50 |
| Asset Growth Rate (YoY) | -14.2% |
| Total Assets | $7.20 Million |
| Market Capitalization | $25.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cynata Therapeutics Limited's assets at a significant premium ( 3.50x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cynata Therapeutics Limited's assets decreased by 14.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cynata Therapeutics Limited (2007–2025)
The table below shows the annual total assets of Cynata Therapeutics Limited from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $7.20 Million | -14.19% |
| 2024-06-30 | $8.39 Million | -55.84% |
| 2023-06-30 | $18.99 Million | -28.46% |
| 2022-06-30 | $26.55 Million | -11.43% |
| 2021-06-30 | $29.97 Million | +71.47% |
| 2020-06-30 | $17.48 Million | +42.70% |
| 2019-06-30 | $12.25 Million | -24.07% |
| 2018-06-30 | $16.13 Million | +13.18% |
| 2017-06-30 | $14.25 Million | +57.84% |
| 2016-06-30 | $9.03 Million | -1.04% |
| 2015-06-30 | $9.13 Million | -8.07% |
| 2014-06-30 | $9.93 Million | +453.73% |
| 2013-06-30 | $1.79 Million | +76.29% |
| 2012-06-30 | $1.02 Million | -16.51% |
| 2011-06-30 | $1.22 Million | -2.48% |
| 2010-06-30 | $1.25 Million | -12.07% |
| 2009-06-30 | $1.42 Million | -38.98% |
| 2008-06-30 | $2.33 Million | -34.56% |
| 2007-06-30 | $3.56 Million | -- |